-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Celiac disease is an autoimmune- related inflammation of the small intestine, with an incidence ranging from 0.
2% to 2.
0%.
Genetically susceptible people carrying HLA-DQ2 and HLA-DQ8 genes will appear after ingesting wheat and related grain gluten.
Celiac disease symptoms, but not absolute
.
Typical clinical symptoms include diarrhea, weight loss, and malnutrition.
Immune Osteoporotic Diabetes Researchers recently launched a 6-week proof-of-concept study to investigate the therapeutic effect of ZED1227 on celiac disease
ZED1227 is a selective oral transglutaminase 2 inhibitor.
The study investigated the therapeutic effect of 3 doses of ZED1227 compared with placebo on celiac disease
.
Adult celiac disease patients were randomized to receive ZED1227 or placebo after their symptoms were under control, while taking wheat gluten daily
The 10 mg, 50 mg, and 100 mg ZED1227 groups each contained 41 patients, the placebo group contained 40 patients, and 35, 39, 38, and 30 patients in each group received end-point duodenal biopsy sampling
.
ZED1227 treatment can reduce duodenal mucosal damage induced by gluten
ZED1227 treatment can reduce gluten-induced duodenal mucosal damage ZED1227 treatment can reduce gluten-induced duodenal mucosal damage
The effect of ZED1227 treatment on the changes of villus height/crypt depth
ZED1227 treatmentIn this proof-of-concept study, the transglutaminase 2 inhibitor ZED1227 can reduce gluten-induced duodenal mucosal damage in patients with celiac disease
Transglutaminase 2 inhibitor ZED1227 can reduce gluten-induced duodenal mucosal damage in patients with celiac disease.
Original source:
Detlef Schuppan et al.
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
Leave a message here
